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Cholesterol in the Viral Membrane is a Molecular Switch
Governing HIV-1 Env Clustering
Jon Ander Nieto-Garai, Aroa Arboleya, Sara Otaegi, Jakub Chojnacki, Josefina Casas,
Gemma Fabriàs, F-Xabier Contreras, Hans-Georg Kräusslich, and Maier Lorizate*
HIV-1 entry requires the redistribution of envelope glycoproteins (Env) into a
cluster and the presence of cholesterol (chol) in the viral membrane. However,
the molecular mechanisms underlying the specific role of chol in infectivity
and the driving force behind Env clustering remain unknown. Here, gp41 is
demonstrated to directly interact with chol in the viral membrane via residues
751–854 in the cytoplasmic tail (CT751–854). Super-resolution stimulated
emission depletion (STED) nanoscopy analysis of Env distribution further
demonstrates that both truncation of gp41 CT751–854 and depletion of chol
leads to dispersion of Env clusters in the viral membrane and inhibition of
virus entry. This work reveals a direct interaction of gp41 CT with chol and
indicates that this interaction is an important orchestrator of Env clustering.
1. Introduction
HIV-1 is surrounded by a lipid bilayer in which the HIV-1
envelope glycoproteins (Env) are embedded. Env is composed
of two subunits—gp120 or surface glycoprotein and gp41 or
transmembrane glycoprotein—which associate into trimers. The
transmembrane gp41 subunit is responsible for the virus-to-
cell and cell-to-cell fusion in the HIV-1 replication cycle, and it
contains the epitopes for a wide variety of broadly neutralizing
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antibodies.[1,2] This makes gp41 a great tar-
get for the development of prophylactic
vaccines against HIV-1 and antiretroviral
drugs targeting the entry of the virus into
the host cell.
HIV-1 particles contain between 7 and 14
Env trimers, a very low number compared
to other enveloped viruses.[3,4] This prop-
erty, which is thought to provide an evolu-
tionary advantage to avoid detection by the
immune system of the host organism[5,6]
has in contrast a limiting effect on the fu-
sion capacity of the virus. Membrane fu-
sion is an energetically demanding process
and in most viral strains a single Env trimer
is not sufficient for inducing efficient vi-
ral entry.[7] To ensure proper fusion, HIV-1
seems to compensate for its low trimer
number by inducing a redistribution of
Env into a single focus upon virus matu-
ration, in a process known as Env cluster-
ing. This clustering is thought to facilitate
the coordinated action of several neighbor-
ing Env trimers and facilitate fusion.[8] Al-
though several factors have been shown
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to be important for clustering, the precise molecular mechanism
governing this process has not yet been fully elucidated.
HIV-1 acquires its lipid envelope from the plasma mem-
brane of the producer cell,[9] but the viral membrane shows
significant differences both in composition and physicochemi-
cal properties compared to its donor membrane.[10,11] It is en-
riched in phosphatidylserine, sphingomyelin, hexosylceramide,
saturated species of phosphatidylcholine,[12,13] and phosphatidyli-
nositol (4,5) biphosphate.[14,15] Additionally, although not neces-
sarily enriched, cholesterol (chol) constitutes up to 50% of the to-
tal lipid molecules in the viral membrane.[12,13] The high amount
of saturated phosphoglycerolipids, sphingomyelin, and chol in
the HIV-1 membrane has led to its comparison with chol-rich
raft-like nanodomains, an idea that is further supported by the
ordered lateral membrane structure (lo phase) found in HIV-
1.[16] Several compounds that alter membrane properties such
as its structure and rigidity have been shown to inhibit virus
infectivity at the entry step,[17–19] including lipidomimetic com-
pounds that specifically alter membrane fluidity.[20] These reports
demonstrate that modulation of membrane fluidity and struc-
tures can be a valid approach for the development of antiretroviral
compounds.[21] Additionally, depletion[22–25] or sequestering[26,27]
of chol—a known regulator of membrane structure—from the
viral membrane has also been found to inhibit viral entry. How-
ever, the precise molecular mechanism underpinning the role of
chol in viral infectivity has not been deciphered yet.
Chol and chol-rich membrane nanodomains have been de-
scribed to laterally self-aggregate different proteins in the plasma
membrane to regulate their function.[28–30] Thus, the role of chol
in infectivity could be related to Env distribution or function.
Indeed, Env has been suggested to associate with raft-like nan-
odomains applying indirect methods based on isolation of deter-
gent resistant membranes (DRMs).[31–34] However, the study of
protein–lipid interactions by DRMs relies on the use of low tem-
perature and detergents,[35] which can alter the natural structure
of membranes and produce artifacts.[36] Thus, they do not consti-
tute direct proof of an interaction of gp41 with chol in the native
viral membrane.
Here, we have found that gp41 directly interacts with chol in vi-
ral particles via residues 751–854 in its cytoplasmic tail (CT). Fur-
thermore, we have shown by super-resolution nanoscopy (STED)
that both the gp41 CT751–854 and chol in the viral membrane are
necessary for efficient clustering of Env and full entry compe-
tence. Altogether, these results support a mechanism by which
interaction of gp41 with chol in the viral membrane drives lateral
self-aggregation and clustering of Env trimers, facilitating fusion
with the host cell and consequent viral entry, revealing chol as
an essential component of the molecular platform driving Env
clustering.
2. Results
2.1. HIV-1 gp41 Interacts with Chol in the Viral Membrane
Chol constitutes up to 50% of the total lipids in the HIV-1 vi-
ral membrane and is necessary for infectivity. Conceivably, chol
may directly interact with viral membrane proteins and trigger
HIV-1 membrane protein activity. The main candidate for this is
Env and specifically its transmembrane subunit gp41, the pro-
tein responsible for membrane fusion. To test if a direct inter-
action between Env and chol exists, we first studied the interac-
tion of gp41 with membrane chol in virus-producing cells using
a well-established photoaffinity binding strategy using a bifunc-
tional photoactivatable and radioactively (tritiated) labeled chol
analogue ([3H]-photochol).[36] A potential gp41–lipid interaction
was studied when Env was expressed alone or in a proviral con-
text to determine an influence of other viral proteins. HEK 293T
were transfected with either a proviral pCHIV plasmid or an Env
only expressing plasmid (Table S1, Supporting Information). Vi-
ral protein-expressing cells were then incubated with the chol
analogue [3H]-photochol for 18 h to allow sufficient lipid capture
and incorporation into the membranes (Figure S1, Supporting
Information). Cells were irradiated with ultraviolet light, thereby
cross-linking proteins and lipids in close proximity (<3 Å). A
comparison of the protein signal in the Western blot with the
lipid signal in the autoradiography demonstrated that wild-type
gp41 directly interacted with chol in cells expressing all of the vi-
ral proteins (Figure 1a, proviral). Notably, this interaction was also
observed when Env was expressed alone (Figure 1a, Env only), re-
vealing that the chol-interacting properties are intrinsic to gp41
and do not require the presence of other viral proteins. When Env
was expressed alone, two additional bands of ≈25 and ≈20 kDa
recognized by the anti-gp41 antibody were also found to interact
with chol. As explored below in viral particles, these proteins are
probably derived from the full-length protein by partial degrada-
tion of regions comprising the CT.[37]
Next, we studied if this interaction is maintained in released
viral particles. For this purpose, the culture supernatant of virus-
producing cells was collected, irradiated to induce lipid–protein
cross-linking, and viral particles were purified on OptiPrep ve-
locity gradients. Next, photoactivatable lipid incorporation into
the viral particles was quantified by a scintillation counter, and
[3H]-photochol was found to constitute 0.13% of the total chol
molecules in these viral particles (see Supporting Experimen-
tal Section, Supporting Information for details). To study in-
teraction, gp41 and the cross-linked chol were immunoprecipi-
tated from viral particles and detected by Western blot and au-
toradiography, respectively (Figure 1b). The results revealed that
gp41—whose identity was confirmed by proteomic analysis (Fig-
ure S2, Supporting Information)—maintained the direct interac-
tion with chol in extracellular viral particles. In addition to gp41,
another protein of ≈20 kDa recognized by the anti-gp41 antibody
was found to also interact with chol. Previous studies have iden-
tified an ≈20 kDa gp41-derived protein to comprise a fragment
of the gp41 CT (Tr-Env-CT).[37] To determine whether the chol-
bound protein in the current study corresponds to this 20 kDa
protein, the corresponding band was submitted to proteomic
analysis. This experiment confirmed that the chol-bound 20 kDa
protein corresponded to Tr-Env-CT, lacking the membrane span-
ning region and the ectodomain (Figure S2, Supporting Informa-
tion). Interestingly, analysis of the relative chol/protein signal of
Tr-Env-CT revealed no significant differences when compared to
full-length gp41 (Figure 1c), suggesting that the chol-interacting
region in gp41 is located in the CT of the protein. Of note, the
25 kDa protein band observed in the Western blot above Tr-Env-
CT (Figure 1b, Ab LC) was identified by proteomic analysis to
correspond to the light chain of the antibody used for immuno-
precipitation, and not to be derived from gp41 (data not shown).
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Figure 1. Gp41 interaction with chol in cells and released mature viral
particles. a) Gp41 was immunoprecipitated from HEK 293T cells fed with
the chol analogue [3H]-photochol and detected by Western blot with the
anti-gp41 chessie-8 antibody (green lanes). The interacting radioactively
labeled lipid was detected by autoradiography of the same membrane
(gray lanes). Cells were transfected either with a proviral pCHIV plasmid
expressing all of the viral proteins or with an Env only expressing pCAGGS
plasmid. b) Viral particles were purified from HEK 293T cells transfected
with the pCHIV proviral plasmid and treated with the chol analogue [3H]-
photochol. Gp41 from input (5% of lysed viral particles), supernatant (SN;
5% of total), and immunoprecipitation (IP) from purified viral particles
were detected by Western blot with the anti-gp41 chessie-8 antibody (green
lane), and the interacting radioactively labeled lipid by autoradiography of
the same membrane (gray lane). Protein bands corresponding to gp160,
gp41, the light chain of the antibody used for immunoprecipitation (Ab
LC), and a truncated form of gp41 (Tr-Env-CT) are labeled. c) Quantifica-
tion of the chol/protein signal ratio of the Tr-Env-CT protein fragment com-
pared to the full-length gp41. The bars and whiskers represent the mean
± SD of experiments from five independent viral purifications (n = 5). Sta-
tistical significance was assessed by analysis of variance and Tukey test.
2.2. Truncation of Residues 751–854 in Gp41 Cytoplasmic Tail
Inhibits Protein Interaction with Chol
Following the discovery that Tr-Env-CT interacts with chol at the
same level as the full-length protein, we next investigated the
involvement of the gp41 CT in the interaction. Specifically, we
focused on the role that the three amphipathic 𝛼-helixes in the
CT (known as lentiviral lytic peptides or LLP) may play in the
interaction, as they have been described to 1) have membrane-
binding properties[38–40] and 2) to be partially embedded in the
membrane.[41–43]
For this purpose, two truncation variants of gp41 were con-
structed, 1) ΔCT811, with a stop codon at residue 812, lacking
the C-terminal 43 amino-acid residues of the CT including LLP1;
and 2) ΔCT750, with a stop codon at residue 751, lacking the C-
terminal 104 amino-acid residues, including all three LLP se-
quences and 14 residues upstream (Figure 2a, Table S1, Sup-
porting Information). Proviral pCHIV plasmids containing these
truncations were used to produce and purify viral particles, and
interaction between gp41 and chol was studied as described
above. Comparison of the Western blot and autoradiography sig-
nals (Figure 2b), and quantification of the relative chol/gp41 sig-
nals of the ΔCT811 and ΔCT750 truncation variants compared
to the wild-type protein revealed that truncation of the last 104
amino-acid residues (ΔCT750) induces a loss of direct chol inter-
action by >70%. This loss of interaction was not due to a defect in
protein or lipid incorporation into the virus particles, as demon-
strated by Western blot (Figure S3, Supporting Information) and
lipidomic analysis (Figure S4, Supporting Information) of puri-
fied viral particles, respectively. Truncation of only the C-terminal
43 amino-acid residues (ΔCT811) did not affect gp41–chol inter-
action (Figure 2c), indicating that LLP1 is not required for chol
binding. These results revealed that the gp41 CT and specifically
the region comprising the LLP 𝛼-helixes is required for the inter-
action of gp41 with chol; since LLP1 is not required, it appears
most likely that LLP2 and/or LLP3 are the primary determinants
for this interaction.
Next, we investigated whether the cholesterol recognition
amino acid consensus (CRAC) domain within the membrane
proximal external region (MPER) of gp41, which has been shown
to interact with chol in different in vitro studies[44–47] played any
role in the interaction of gp41 with chol. For this purpose, the
“LWYIK” CRAC domain in the full-length gp41 was disrupted
by introducing a conservative mutation (L677I) that has been
described to hamper interaction of CRAC-derived peptides with
chol, and to cause an inhibition of fusion in cells expressing the
gp41 CRAC mutant.[48] Viral particles containing this mutation
were purified, and chol interaction was studied. Disruption of the
CRAC domain was not found to have an effect on the interaction
of gp41 with chol (Figure S5, Supporting Information), exclud-
ing the CRAC domain in MPER as the region responsible for the
interaction in viral particles in the steady state.
2.3. Gp41 Palmitoylation in the Cytoplasmic Tail Is Not
Necessary for Chol Interaction
Gp41 has been described to be palmitoylated on up to two
cysteine residues in the CT, and this palmitoylation has been
suggested to drive Env targeting to DRMs.[32,33] The truncated
ΔCT750 gp41 variant, which does not interact with chol, lacks the
C762 residue described to be palmitoylated. To establish if the
loss of interaction derived from the truncation of the CT751–854 re-
gion is related to the lack of gp41 palmitoylation, we investigated
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Figure 2. Effect of partial CT truncation in gp41 interaction with chol in purified mature viral particles. a) Schematic illustration of gp41 CT trun-
cation mutants. The ΔCT811 variant contains a L812: stop codon substitution and lacks the last 43 amino-acid residues of the cytoplasmic tail.
The ΔCT750 variant contains a L751: stop codon substitution and lacks the last 104 amino-acid residues of the cytoplasmic tail. b) Gp41 from in-
put (5% of lysed viral particles) and immunoprecipitation (IP) from viral particles were detected by Western blot with the anti-gp41 chessie-8 an-
tibody (green lane), and the interacting radioactively labeled lipid by autoradiography of the same membrane (gray lane). c) Quantification of the
chol/protein signal ratio of the truncated gp41 proteins ΔCT811 and ΔCT750 compared to the wild-type gp41. The bars and whiskers represent the
mean ± SD of experiments from three independent viral purifications (n = 3). Statistical significance was assessed by analysis of variance and Tukey
test.
the impact of palmitoylation on the gp41–chol interaction. For
this purpose, a pCHIV variant containing a substitution of the
palmitoylated cysteine residue by a serine in position 762 (C762S)
was constructed (Table S1, Supporting Information).
First, we determined the effect of the C762S substitution on
gp41 palmitoylation by use of an alkyne-modified clickable palmi-
toyl analogue, 15-hexadecynoic acid. This fatty acid was fed to
virus-producing cells to become incorporated into cellular lipid
metabolism and thus be a substrate for gp41 palmitoylation.
Viral particles were purified from treated virus-producing cells
and gp41 was immunoprecipitated. Gp41 palmitoylation was de-
tected by copper-dependent click chemistry. Western blot analysis
showed that wild-type gp41 protein was efficiently palmitoylated,
while the gp41 C762S variant completely lost palmitoylation (Fig-
ure 3a, protein signal and palmitoylation in red and green, re-
spectively). Quantification of the relative palmitoyl/gp41 signals
confirmed that the C762S substitution led to a loss of gp41 palmi-
toylation (Figure 3b).
We next investigated whether the loss of palmitoylation had
any effect on the interaction of gp41 with chol. Viral particles
containing the gp41 C762S variant were purified, and interaction
with chol was studied as above. Comparison of the Western blot
and autoradiography signals showed that the C762S variant in-
teracted with chol at a level equivalent to that observed for the
wild-type protein (Figure 3c), demonstrating that palmitoylation
of gp41 at the C762 residue is not required for the interaction
with chol. Furthermore, lack of palmitoylation of gp41 also did
not have an effect on gp41 incorporation into the virus (Figure
S6, Supporting Information).
2.4. Chol Interaction Does Not Depend on Maturation
Virus maturation is a process concomitant with budding of the
viral particle from the producing cell and governs Env mobility
in the membrane[49] and Env clustering.[8] To establish whether
the maturation state of the virus has an effect on gp41 associ-
ation with chol, we investigated whether this interaction is also
observed in immature viral particles containing a mutation in the
viral protease. Mature and immature particles containing either
wild-type or truncated (ΔCT750) gp41 (Figure 4a) were purified,
and chol interaction was studied by Western blot and autoradio-
graphy (Figure 4b). Quantification of the relative chol/gp41 sig-
nal (Figure 4c) revealed that the maturation state of the virus did
not have an effect on gp41–chol interaction. Wild-type gp41 inter-
acted with chol at the same level in mature and immature parti-
cles, and this interaction was lost in both cases when the CT was
truncated. This loss of interaction was not caused by differences
in protein incorporation into the virus (Figure S7, Supporting
Information).
2.5. Gp41 Cytoplasmic Tail and Chol Govern Envelope Clustering
Although maturation dependent Env clustering has been shown
to be necessary for efficient viral entry of wild-type HIV-1 and the
gp41 CT is involved in this process,[8] the mechanism that gov-
erns Env clustering and the specific role of the gp41 CT in this
process has yet to be elucidated. Given the importance of chol
for viral infectivity and its binding to the gp41 CT, we wanted to
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Figure 3. Effect of the C762S substitution on gp41 palmitoylation and gp41–chol interaction in purified mature viral particles. a) Gp41 from input (5%
of lysed viral particles) and immunoprecipitation (IP) from viral particles treated or not with the clickable palmitoyl analogue precursor 15-hexadecynoic
acid were detected by Western blot with the anti-gp41 chessie-8 antibody (red), and the palmitoyl group of the protein was detected by the covalent
binding of a IRDye800 azide fluorescent probe mediated by a click-chemistry reaction (green). b) Quantification of the palmitoyl/protein signal ratio of
the mutated gp41 protein C762S compared to the wild-type gp41 from either treated or untreated viral particles. The bars and whiskers represent the
mean ± SD of experiments from three independent viral purifications (n = 3). Statistical significance was assessed by analysis of variance and Tukey
test. c) Gp41 from input (5% of lysed viral particles) and immunoprecipitation (IP) from viral particles were detected by Western blot with the anti-gp41
chessie-8 antibody (green lane), and the interacting radioactively labeled lipid by autoradiography of the same membrane (gray lane).
Figure 4. Effect of virus maturation on the CT751–811 dependent gp41 interaction with chol in purified viral particles. a) Schematic illustration of mature
and immature viral particles containing either the full-length wild-type gp41 or the truncated ΔCT750 gp41. b) Gp41 from immunoprecipitation from
mature or immature viral particles were detected by Western blot with the anti-gp41 chessie-8 antibody (green lane), and the interacting radioactively
labeled lipid by autoradiography of the same membrane (gray lane). c) Quantification of the chol/protein signal ratio of the wild-type and truncated
ΔCT750 gp41 proteins in mature and immature viral particles. The bars and whiskers represent the mean ± SD of experiments from three independent
viral purifications (n = 3). Statistical significance was assessed by analysis of variance and Tukey test.
determine whether the gp41–chol interaction could be the under-
lying mechanism governing Env clustering. To this end, the effect
of the ΔCT750 truncation and of chol interaction on Env cluster-
ing was studied by analyzing Env distribution in viral particles us-
ing STED super-resolution nanoscopy. Individual viral particles
were identified by pseudotyping with the viral accessory protein
Vpr tagged with enhanced green fluorescent protein (Vpr.eGFP).
To study Env clustering, viral particles containing either wild-type
or truncated ΔCT750 gp41 variants were immunolabeled against
Env (Figure 5a,b). Acquisition of Env signal (red) and Vpr.eGFP
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Figure 5. Env distribution patterns of virus particles with full-length or the
truncated ΔCT750 gp41 and its effect on entry. a,b) Representative images
of Vpr.eGFP (green) and Env (orange) signal of virus particles with full-
length and the truncated ΔCT750 gp41, respectively. c) Env distribution
patterns of virus particles with full-length and the truncated ΔCT750 gp41,
with and without Cholesterol oxidase (COase) treatments. The number of
viral particles quantified in each preparation is represented above the bars
(n > 80). The statistical significance was assessed by 𝜒2 test for indepen-
dence at two degrees of freedom. Images show examples of virus particles
for each Env distribution class. Scale bars: 100 nm. d) Schematic represen-
tation of Env cluster dispersion caused by gp41 ΔCT750 truncation, and by
conversion of chol to cholestenone by COase. Viral membrane in red, Env
trimers in orange, chol molecules in blue, and cholestenone molecules in
green. e) Effect of ΔCT750 truncation and COase treatment in entry ca-
pacity of concentrated BlaM.Vpr mature viral particles. For each variant,
a viral amount corresponding to 30 ng of CA was incubated with Jurkat
E6-1 cells. As a control, viral particles lacking Env (Env(−)), and WT viral
particles treated with the entry inhibitor AMD3100 (WT+AMD3100) were
used. COase-treated viral particles were incubated with 0.5 U of COase
for 30 min at 37 °C. Untreated viral particles were incubated for 30 min
at 37 °C without enzyme. The relative fluorescent intensity ratios of the
cleaved (blue) and uncleaved (green) Vpr.BlaM fluorescent substrate CCF2
loaded into the cells was measured for each variant. The bars and whiskers
represent the mean ± SD of experiments from five independent viral pu-
rifications (n = 5) with four replicas each. Statistical significance was as-
sessed by analysis of variance and Tukey test.
signal (green) confirmed that the ΔCT750 truncation induced a
shift toward a dispersed distribution and loss of clustering when
compared to the wild-type protein (Figure 5c), as reported for an-
other CT truncation in a previous study.[8] Immature viral parti-
cles exhibited a broadly distributed Env pattern independently of
the gp41 variant as reported before[8] (Figure S8, Supporting In-
formation), which may be explained by the sequestering of Env by
the underlying rigid Gag lattice in immature viral particles.[49,50]
Of note, ≈20% of the immature viral particles, as well as the trun-
cated ΔCT750 gp41 variant, were categorized as single focus parti-
cles. We expect this residual clustering to be derived in part from
a resolution limit in the STED clustering assay, which cannot dif-
ferentiate Env distribution to the molecular level. This residual
clustering (≈20%) would thus represent a lack of sensitivity in
the assay to resolve Env molecules that are dispersed, but sepa-
rated by a distance (≈10–20 nm) lower than the resolution limit
of the technique (≈40 nm).
To determine whether the gp41 CT interaction with chol is re-
quired for Env clustering, we investigated the effect of chol de-
pletion on Env distribution in the viral membrane. For this pur-
pose, Vpr.eGFP viral particles immunolabeled against Env were
treated with cholesterol oxidase (COase). In contrast to other chol
depleting agents such as 𝛽-cyclodextrin, COase does not remove
chol molecules from the membrane and thus does not change
the total lipid molecules in the virus. This enzyme converts up
to 50% of the viral membrane chol into cholestenone,[51] remov-
ing the polar hydroxy chol headgroup that is known to interact
with proteins.[52] The headgroup was previously shown to also
be important for the self-aggregation of HIV-1 gp41-derived pep-
tides in the presence of chol-rich model membranes.[53] Treat-
ment with COase of wild-type viral particles carrying the already
clustered Env proteins revealed that partial conversion of chol to
cholestenone caused dispersion of the clustered Env. In contrast,
no significant additional effect was observed regarding the dis-
tribution of the already disperse truncated ΔCT750 gp41 variant
(Figure 5c). These results indicated that the interaction between
the CT751–854 region of gp41 and chol is necessary for efficient
Env clustering, and depletion of chol from the viral membrane
disaggregates the already created Env clusters.
We next investigated whether the loss of Env clustering also
resulted in a loss of entry capacity. This was analyzed using the
BlaM assay,[54] which detects cytoplasmic entry of a modified 𝛽-
lactamase incorporated into the virion by cleavage of a BlaM sub-
strate. For this purpose, viral particles carrying Vpr fused with
the 𝛽-lactamase enzyme (Vpr.BlaM) were produced. Compara-
tive entry experiments were performed on Jurkat E6-1 cells for
particles carrying wild-type gp41 or the ΔCT750 gp41 variant and
treated or not with COase. After loading with the 𝛽-lactamase
fluorescent substrate CCF2, the entry capacity of the viral par-
ticles was calculated as a relative fluorescent intensity ratio of the
cleaved (blue) and uncleaved (green) fluorescent substrate. Fig-
ure 5d shows that the ΔCT750 truncation or partial conversion of
chol to cholestenone in the viral membrane by the COase resulted
in a significant decrease (>70% and ≈60%, respectively) in viral
entry capacity, indicating that inhibition of the gp41–chol interac-
tion hampers HIV-1 entry, in accordance with the observed loss
of Env clustering.
3. Discussion
Upon maturation, HIV-1 Env trimers redistribute into a single
cluster, facilitating fusion with the host cell.[8] Although several
factors seem to regulate this clustering, little is known about the
molecular mechanisms governing this process. Chol, one of the
main lipids in HIV-1, is also a key requirement for infectivity,
but the molecular mechanism explaining its precise role in the
entry process is currently not well understood. Here, we have
studied the interaction of gp41 with chol in the viral membrane
and the role of this interaction for the redistribution of Env upon
maturation.
The gp41 CT is unusually long when compared to the related
retroviruses and the conserved sequences in it suggest it to be a
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key component of the protein. During viral morphogenesis, the
gp41 CT is important for incorporation of the protein into bud-
ding sites, either by direct interaction with the underlying Gag
matrix[55–57] or by its preferential partitioning into specific lipid
nanodomains created or selected by Gag.[58] Once incorporated
into the virus, the gp41 CT also regulates protein activity and
distribution.[8] Additionally, the gp41CT has been postulated to
be involved in the interaction with chol in the viral membrane
based on the partitioning of Env into DRMs,[34] but direct inter-
action of gp41 with chol in the native viral membrane has not
been observed so far.
Using a well-established photoaffinity strategy with a bifunc-
tional photoactivatable chol analogue, we have proven that gp41
directly interacts with chol both in virus-producing cells and
in released purified viral particles. The photoactivatable [3H]-
photochol incorporated into viral particles was found to consti-
tute only around 0.13% of the total chol molecules in the virus,
which supports the notion that cross-linking of the lipid with
gp41 detects specific interaction with chol, and is not an artifact
due to the high chol amount (≈50%) in the virus membrane. Ad-
ditionally, we found that this interaction is mediated by the gp41
CT, and a peptide corresponding only to the CT was also cross-
linked to chol within viral particles. We further demonstrated that
the region comprising residues 751–854 in the gp41 CT, and in
particular the region containing LLP2 and 3, is responsible for the
interaction, while LLP1 appears to be dispensable. All three LLP
𝛼-helixes have membrane-binding properties[38–40] and are par-
tially embedded in the inner leaflet of the viral membrane,[41–43]
which supports their role in the interaction of gp41 with chol.
Furthermore, previously published work has shown that selective
pressure results in HIV-1 partially overcoming the antiretroviral
effect of a chol-binding compound, amphotericin B methyl es-
ter (AME), by developing truncations in the gp41 CT. This AME
resistant mutant is generated by cleavage of the last 104 amino-
acid residues in gp41 CT—equivalent to the ΔCT750 gp41 variant
in our work—by the viral protease,[59] strongly suggesting a rela-
tionship between gp41 CT and chol. Indeed, the results obtained
in our work could provide a more in depth explanation of this
effect. When AME binds and sequesters chol in the viral mem-
brane, the Env trimers interacting with chol via the gp41 CT751–854
region are also sequestered by extension, which hampers their
activity and function. Truncation of the gp41 CT751–854 would in
contrast uncouple the Env trimers from the chol molecules se-
questered by AME, allowing their diffusion. As explained be-
low, this CT truncated viral particles could retain fusion activity
in certain cell types by an increased incorporation of Env into
the virion—partially overcoming the necessity to cluster, by a
receptor-induced Env clustering, or by a combination of both.
Interestingly, the canonical chol-binding CRAC domain lo-
cated in the gp41 MPER, previously shown to bind chol
molecules in in vitro studies,[44–47] was not found to be required
for gp41–chol interaction in mature viral particles in the steady
state. One possible explanation for this discrepancy relies on the
fact that these reports studied the interaction of CRAC with lipids
using indirect in vitro techniques such as localization of Env to
DRMs,[45] binding of CRAC-derived peptides to membranes,[47]
binding of peptides to agarose-immobilized chol derivatives,[44]
or antibody binding assays with CRAC mutated gp41 proteins.[46]
None of these techniques provide absolute proof of the associa-
tion of gp41 with chol or chol-enriched nanodomains, nor of the
specific role of the CRAC domain in said interaction, in func-
tional viral particles. The observed differences could additionally
be explained by the fact that our study was carried out with free
viral particles, where Env was not engaged to cellular receptors.
It cannot be excluded that the CRAC sequence could play a role
in protein–lipid interaction in other protein conformations, such
as during Env trafficking in viral morphogenesis or when Env is
in an intermediate fusion state.
Since chol and chol-rich nanodomains are important regula-
tors of the function and localization in the membrane of several
proteins,[28–30] we next tried to pinpoint the physiological rele-
vance of the gp41–chol interaction in HIV-1. Using Env local-
ization analysis by STED nanoscopy, we determined that trunca-
tion of the chol-interacting CT751–854 region inhibited clustering
of Env inducing a dispersed phenotype. Previous reports have
suggested that a cross-talk between gp41 CT and the underlying
MA lattice,[55,60] or interaction between trimers via the CT[8] could
be the driving force behind the redistribution of Env, but here we
demonstrate that the already clustered wild-type Env acquires a
dispersed phenotype after chol depletion caused by the treatment
with COase. A general assumption is that chol is able to fluidize
membranes composed of lipids with long saturated chains, such
as those present in HIV-1, so conversion of chol to cholestenone
by COase should lead to an increased rigidity of the HIV-1 mem-
brane. Even with this rigidification and the derived decreased pro-
tein mobility in the membrane,[49] the already clustered wild-type
Env trimers disperse after the COase treatment, further support-
ing the suggestion that the specific interaction of chol with gp41
is critical for clustering while gp41 CT–MA or CT–CT interac-
tions alone, which should be intact in the COase-treated wild-type
virus, are not sufficient.
Viral entry assays showed that inhibition of Env clustering,
either by truncation of the CT or depletion of chol, resulted in
decreased entry presumably by hindering the coordinated action
of Env trimers, as reported before.[8] Interestingly, as introduced
above, previous studies found that truncation of gp41 CT can ren-
der fully infectious viral particles in certain cell types,[57,59] which
seems to be coupled with an increased incorporation of Env into
the virus.[8,57] Env clustering is suggested to be an evolutionary
mechanism to overcome the low number of Env trimers in the
virus, so retention of infectivity in certain cell types after CT trun-
cation may be explained by the increased number of incorporated
Env trimers induced by the mutation. This could in turn permit
the coordinated action of several neighboring trimers without the
need to distribute them into a cluster. Nevertheless, this effect is
highly cell-type dependent and is only observed in some appropri-
ately called “permissive” cells, while “non-permissive” lympho-
cytes such as the Jurkat cells used in our work, among others,
require the gp41 CT for infectivity.[57,61] Similarly, the residual
fusion observed in the truncated gp41 variant can be explained
by the fact that Env dispersion caused by complete CT truncation
of gp41 has previously been shown to be partially rescued after
engagement with cellular receptors.[8] This is probably due to re-
tention of Env trimers once they have engaged with CD4 recep-
tors, ultimately presenting a receptor-induced clustered pheno-
type. This would be facilitated by the increased mobility of Env
in the viral membrane after virus maturation[49] and by the in-
creased incorporation of the truncated Env into the viral particles.
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This receptor-induced clustering would allow the virus to retain
residual fusion capabilities after engagement to the host cell.
Our findings demonstrate that Env clustering requires the in-
teraction of gp41 with chol in the viral membrane, which could
explain the mechanism of action of several antiretroviral drugs
that deplete[22–25] or sequester[26,27] chol, or target the structure
and properties of raft-like lipid nanodomains[20] by providing a
link between chol in the viral membrane and viral entry. Addi-
tionally, our findings come in excellent agreement with and pro-
vide further insight to a recent study that demonstrated that the
entry inhibitory effect of SERINC5, a host cell protein incorpo-
rated into the virus, is based in its disruption of Env clusters.
Based on the observation that SERINC5 did not codistribute with
Env the authors conclude that its effect in clustering is indirect,
and hypothesize that its effect could be based on sequestering of
viral membrane chol by SERINC5.[62] Our results directly sup-
port the hypothesis that sequestering of chol by SERINC5 would
remove the molecular switch driving Env redistribution and ham-
per entry.
We anticipate that the approach followed in our work could
shed new light into how protein–chol interactions in the vi-
ral membrane could regulate glycoproteins functions in other
viruses. In influenza, the fusion protein hemagglutinin also
seems to interact with chol,[63] and modulation of chol-mediated
membrane properties has been found to disrupt infectivity in the
virus,[64] suggesting that a direct interaction with chol could also
regulate protein function and infectivity in this virus. Chol has
also been shown to be a key component of viral infectivity in
Ebola virus, where it tightly regulates assembly of new viral par-
ticles in the plasma membrane by targeting the viral GP proteins
to chol-rich nanodomains[65] and recently, in SARS-CoV-2, it has
been found to be an important requisite for infectivity by induc-
ing trafficking of ACE2 to viral endocytic entry points, as well as
increasing SARS-CoV-2 binding to the cells.[66]
4. Conclusion
Collectively, our results reported here support a maturation de-
pendent Env clustering mechanism governed by the interaction
of gp41 with chol in the viral membrane via the CT751–854 region
(Figure 6a). In an immature state, the underlying rigid Gag lattice
sequesters Env trimers in place, not allowing their diffusion and
redistribution. Upon virus maturation and Env release from the
Gag lattice, the now-free-to-diffuse Env trimers[49] associate into a
cluster driven by their lateral self-aggregation induced by their in-
teraction with chol. This clustering facilitates an efficient fusion
with the host cell, viral entry, and infectivity (Figure 6b). Since the
interaction between gp41 and chol is mediated by residues 751–
854 in the CT, truncation of this region induces a loss of inter-
acting capacity with chol. Upon maturation and increase of Env
mobility, because the truncated gp41 cannot interact with chol,
it does not coalesce into a single cluster, remaining dispersed in
the viral membrane. If the number of Env molecules in the virus
remains low, dispersion of Env hampers or delays coordinated ac-
tion of several trimers, decreasing viral and host cell membrane
fusion and entry (Figure 6c). Similarly, depletion of chol from the
viral membrane removes the driving force behind Env clustering,
inducing a dispersion of the already clustered wild-type gp41 and
thus also inhibiting clustering and subsequent entry (Figure 6d).
This chol dependent clustering could be explained by several
related molecular mechanisms. After virus maturation, the in-
teraction of gp41 with chol could drive its partitioning into spe-
cific lipid nanodomains, inducing a clustering of Env trimers.
Alternatively, interaction of gp41 with chol could act as a nucle-
ation site for the generation of new protein–lipid nanodomains to
which neighboring Env trimers and chol molecules are recruited.
Due to the small size of the viral particles and even smaller size
of protein–lipid nanodomains, elucidating the specific molecu-
lar mechanism would necessitate super-resolution fluorescence
nanoscopy techniques with much higher spatiotemporal resolu-
tion capabilities.
5. Experimental Section
Experimental Design: The main goal of this work was to unravel
whether interaction of gp41 with chol was the driving force governing Env
clustering. To accomplish this, the authors studied and demonstrated the
direct interaction of gp41 in viral particles with viral membrane chol by
using a functionalized photoactivatable chol analogue. The authors then
further determined the region involved in the interaction by truncation of
the CT of gp41 and mutations in several other regions of interest. To deter-
mine whether the gp41–chol interaction was the driving force behind Env
clustering, the effect of the disruption of this interaction in the distribution
of Env in the virus was analyzed using super-resolution STED nanoscopy.
The authors finally established the biological outcome of Env clustering
studying the entry capacity of the viral particles using a BlaM assay.
Plasmids and Cells: Non-infectious HIV-1 particles were producing us-
ing the pCHIV plasmid,[67] which expressed all of the HIV-1NL4-3 proteins
except Nef, and lacks the long-terminal repeat sequences necessary for
competent replication. pCHIV derivatives were used for studying the effect
of gp41 mutations, and maturation state of the virus. For cellular interac-
tion studies with only the Env protein, HIV-1NL4-3 Env expressing pCAGGS
construct was used. Viral particles pseudotyped with BlaM.Vpr for entry ca-
pacity studies were produced by cotransfection with pMM310 plasmid. Vi-
ral particles pseudotyped with eGFP.Vpr for Env distribution studies were
produced by cotransfection with eGFP.Vpr plasmid. Detailed information
on all of the constructs is listed in Table S1, Supporting Information.
293T cells were maintained at 37 °C and 5% CO2 in DMEM Gluta-
MAX High Glucose culture medium supplemented with 10% FBS, and
100 U mL−1 Penicillin–Streptomycin. Jurkat E6-1 cells were maintained
at 37 °C and 5% CO2 in RPMI 1640 GlutaMAX culture medium supple-
mented with 10% FBS, and 100 U mL−1 Penicillin–Streptomycin.
Viral Particle Purification: 293T at 60% confluency were transfected
with the proviral pCHIV plasmid by calcium phosphate precipitation. Viral
particle purification was carried out as described before.[20,68,69] Briefly,
culture medium was harvested, cleared by filtration, and viral particles
were concentrated by ultracentrifugation through a cushion of 20% w/v
sucrose. Pelleted HIV-1 particles were resuspended and further purified
by velocity gradient purification using an OptiPrep gradient (Axis-Shield).
The visible virus fraction was collected, pelleted by ultracentrifugation, re-
suspended in 150 mm NaCl, 10 mm Hepes pH 7.4, aliquoted, frozen in
liquid nitrogen, and stored at −80 °C. Virus particle concentration was de-
termined by an anti-CA Western blot.
Gp41–Chol Interaction Assay by Photoaffinity Labeling: For gp41–chol
interaction studies 293T cells were transfected in 10 cm dishes with either
an Env expressing pCAGGS plasmid (4 µg/dish) or a proviral pCHIV plas-
mid (10 µg/dish) as described before. 16 h after, transfection cells were
incubated with 100 µCi/dish of [3H]-photochol diluted in 10 mL/dish of
culture medium supplemented with 10% delipidated FBS for 24 h. Then,
the culture medium containing the viral particles was collected. Cells were
washed with PBS, and irradiated with UV light (360 nm) in ice cold PBS for
5 min to induce cross-linking; afterwards cells were scraped, pelleted, and
lysed with a modified RIPA buffer (20 mm HEPES, 100 mm NaCl, 5 mm
EDTA, 0.5% w/v sodium deoxycholate) for 1 h at 4 °C. The culture medium
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Figure 6. Env clustering depends on CT751–811 mediated chol interaction and maturation state. a) Schematic illustration of the CT751–854 region respon-
sible for gp41–chol interaction. b) In wild-type HIV-1 particles, the full-length gp41 protein interacts with viral membrane chol via the CT751–854 region.
Upon maturation, Env trimers are free to diffuse and coalesce into a single focus mediated by their interaction with chol. This clustering enables efficient
fusion with the host cell. c) When the CT751–854 region is truncated, the protein loses the capacity to interact with chol. Upon maturation, truncated Env
trimers cannot coalesce into a single focus as they are excluded from chol-rich domains. The absence of an Env cluster results in a defect in fusion with
the host cell. d) Disruption of the gp41–chol interaction by treatment of wild-type HIV-1 particles with COase and conversion of chol to cholestenone,
induces a dispersion of the already clustered Env particles, resulting in a phenotype similar to the truncated Env trimers.
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containing viral particles was cleared by filtration, irradiated with UV light
for 5 min at 4 °C to induce cross-linking, and viral particles were purified
as before. After purification yield quantification, viral particles equivalent
to 1 µg of CA were lysed with modified RIPA buffer for 1 h at 4 °C. 5% of
the total volume of lysed cells or viral particles was stored for use as an
input in Western blot and autoradiography studies.
Gp41 was immunoprecipitated from the lysed cellular and viral sam-
ples by incubation overnight at 4 °C with Protein G Sepharose 4 Fast Flow
(GE Healthcare) beads covalently bound to anti-gp41 chessie-8 antibody.
Beads were pelleted, washed, and boiled with SDS-PAGE 6x sample buffer
at 95 °C for 5 min to release the proteins from the beads. The samples
were loaded into an SDS-PAGE (12.5%) for subsequent analysis by West-
ern blotting. After incubation of Western blot membrane with chessie-8
mouse anti-gp41 primary antibody (1:2000 overnight at 4 °C), membrane
was developed with anti-mouse IRDye 800 secondary antibody (1:15 000
for 45 min at RT) diluted in Odyssey Blocking Buffer (LI-COR). Detection
of the proteins was carried out using the LI-COR Odyssey imaging system.
To detect the lipid signal, the Western blot membranes were then dried and
subjected to autoradiography for 18 h in a BetaIMAGER(Biospace Lab).
Gp41 Palmitoylation Assay: Gp41 palmitoylation was studied with the
use of an alkyne-modified clickable palmitoyl analogue, 15-hexadecynoic
acid. 16 h after, transfection 293T cells were treated or not with 500 µm
of 15-hexadecynoic acid diluted in 10 mL/dish of culture medium supple-
mented with 10% delipidated FBS for 24 h. Then, the culture medium con-
taining the viral particles was collected and cleared by filtration, and viral
particles were purified as before. After purification yield quantification, viral
particles equivalent to 1 µg of CA were lysed with EDTA free modified RIPA
buffer (20 mm HEPES, 100 mm NaCl, 0.5% w/v sodium deoxycholate) for
1 h at 4 °C. Gp41 was immunoprecipitated as before, and the palmitoyl
analogue incorporated into gp41 was labeled by a copper-dependent click-
chemistry reaction.[70] Briefly, the immunoprecipitated samples bound to
the beads were incubated with 0.1 mm TBTA, 1 mm Cu(III)SO4, 10 mm
ascorbic acid, and 10 µm of IRDye800 azide fluorescent dye for 1 h at
dark and RT with constant stirring. The beads were then washed and in-
cubated at 60 °C for 5 min with 6x sample buffer containing 150 µm 𝛽-
mercaptoethanol and loaded into an SDS-PAGE. A Western blot was devel-
oped with chessie-8 mouse anti-gp41 primary antibody (1:2000) overnight
at 4 °C and anti-mouse IRDye 800 secondary antibody (1:15 000) for 45 min
at RT diluted in Odyssey Blocking Buffer (LI-COR). Detection of the pro-
teins and clicked palmitoyl analogue was carried out using the LI-COR
Odyssey imaging system, with the protein signal in the 680 channel (red)
and the palmitoyl signal in the 800 channel (green).
Env Distribution Assay: For Env distribution measurements, purified
HIV-1 particles (≈1 µg of CA) were adhered to poly-L-lysine (Sigma)-
coated coverslips for 15 min. Coverslips were blocked using 2% bovine
serum albumin (Sigma)/PBS for 15 min. Particles were stained for Env
using 10 ng µL−1 2G12 Fab fragments, and anti-human Abberior STAR
RED (KK114) conjugated Fab fragments for 1 h each in the blocking buffer.
Following immunostaining, particles were washed in PBS, briefly fixed us-
ing 3% PFA/PBS, overlaid with SlowFade Diamond mounting medium
(Thermo Fisher Scientific) and imaged using STED nanoscopy. All above
steps were carried out at room temperature. For COase treatment, cover-
slip adhered and Env immunostained virus particles were incubated with
0.5 U COase from Streptomyces species (Sigma) for 30 min at 37 °C prior
to washing, post-fixing, and mounting.
Super-resolution analysis of HIV-1 Env distribution was performed us-
ing Leica SP8 STED 3X microscope (Mannheim, Germany) equipped with
a 100 ×/1.4 NA oil immersion STED objective. 2-color STED images of
Env (Abberior STAR RED) and Vpr.eGFP signal were acquired sequentially
for each channel using 637 and 498 nm lines from the white light laser.
Abberior STAR RED and eGPF signal was depleted with a donut-shaped
775 and 592 nm pulsed STED lasers, respectively.
Under these conditions, ≈40 and 100 nm lateral axial resolution (full-
width-at-half-maximum) was achieved in Env (Abberior STAR RED) and
eGFP.Vpr acquisition channels, respectively (estimated from fluorescent
bead and single fluorescent antibody molecule measurements). STED im-
ages were acquired with following parameters: pinhole size: 1 Airy; dwell
time: 1.2 µs pixel−1; and XY pixel size: 20 nm. Following acquisition, STED
images were thresholded and smoothed (Gaussian Blur, radius = 15 nm)
using Fiji (ImageJ distribution) software. Env distribution was assessed by
manual classification of Env signals associated with individual virus par-
ticles into three distribution patterns: a single cluster, two clusters, and
multiple clusters.[8]
Viral Entry Assay: HIV-1 entry assay were performed as described
before.[54] Viral particles pseudotyped with a Vpr-𝛽-lactamase fusion pro-
tein (BlaM.Vpr) were obtained by cotransfection of 293T cells with 10 µg
of pCHIV and 1 µg of pMM310[71] plasmids. Viral particles were con-
centrated and quantified as described before. Viral particles equivalent to
30 ng of CA were added to 105 Jurkat E6-1 cells in a 96 well plate, spinoc-
ulated by centrifugation at 1000 x g for 5 min and incubated for 2.5 h. For
COase treatment, viral particles were incubated with 0.5 U COase from
Streptomyces species (Sigma) for 30 min at 37 °C prior to addition to the
cells. Untreated viral particles were incubated for 30 min at 37 °C without
the enzyme. As negative controls of entry, viral particles lacking Env (ob-
tained with the pCHIV Env(−) construct), and wild-type particles treated
with the entry inhibitor AMD3100 (0.5 µm)[72] were used. After virus in-
cubation, cells were washed and incubated with 60 µL/well of CCF2 𝛽-
lactamase substrate loading solution (Invitrogen; prepared according to
manufacturer’s instructions) for 17 h at room temperature in the dark.
CCF2 𝛽-lactamase substrate cleavage was measured by recording the rel-
ative fluorescence intensities of the substrate (excitation = 409 nm, emis-
sion = 528 nm) and product (excitation = 409 nm, emission = 460 nm).
Background from unstained cells was subtracted, and the relative ratio of
emission intensities at 460/528 nm (product/substrate) was calculated.
Statistical Analysis: For gp41–chol interaction, Env incorporation,
lipidomic analysis, and viral entry assays data were normalized to wild-
type particle signal. In Env distribution studies by STED the number of
particles with each distribution was expressed as a percentage of the total
sample size. The sample size was always n > 3, but the specific n value
for each experiment is detailed in the respective figure and figure legends.
Experimental groups were compared and significance determined by anal-
ysis of variance and Tukey test when more than two samples were com-
pared, and by Student’s t-test when two samples were compared, using
SigmaPlot. Data are represented as means with standard deviation (±SD)
unless otherwise stated. The statistical significance of Env distribution was
assessed by 𝜒2 test for independence at two degrees of freedom.
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